Rezolute, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated January 29, 2019 (signed January 31, 2019), details the closing of a Series AA Preferred Stock financing by Rezolute, Inc. The transaction resulted in a change of control and significant changes to the Board of Directors.
Key Financial Metrics and Transaction Details
- Financing Proceeds: Aggregate gross proceeds of $25,000,000, inclusive of a $1,500,000 exclusivity payment received in December 2018.
- Shares Issued: 1,250,000 Series AA Preferred Shares issued to each of two purchasers (Handok, Inc. and Genexine, Inc.) at $10.00 per share.
- Conversion Terms: Effective conversion price of $0.22 per share of Common Stock. Initial conversion ratio is 45.45454 Common Shares for one Series AA Preferred Share.
- Debt Conversion: Senior secured notes with a principal face amount of $5,340,000 plus accrued interest of $800,117 were automatically converted into 767,515 shares of Series AA Preferred Stock at a 20% discount.
- Ownership Structure: Purchasers collectively own 54% of the Company's Common Stock on an as-converted basis.
Material Changes Versus Prior Period
- Change in Control: The financing triggered a change in control of the Company.
- Board Resignations: Directors Hoyoung Huh, David Welch, Tae Hoon Kim, and Samir Patel resigned from the Board of Directors.
- Board Appointments: Young-Jin Kim (Chairman & CEO of Handok Inc.) and Young Chul Sung, Ph.D. (Founder of Genexine Inc.) were elected to the Board.
- Capital Structure: Issuance of new Series AA Preferred Stock and conversion of existing debt obligations.
Outlook, Risks, and Unusual Items
- Anti-Dilution Protection: The Series AA Preferred Stock includes standard weighted average anti-dilution protection. The conversion price will adjust if the Company issues securities at a price lower than the effective conversion price of $0.22.
- Mandatory Conversion: Shares will automatically convert upon a vote by holders of two-thirds of the voting power of the Series AA Preferred Stock or upon an amendment to the Certificate of Incorporation to increase authorized Common Stock to at least 500,000,000 shares.
- Regulatory Status: Securities were issued pursuant to Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. They are not registered and may not be resold in the U.S. absent registration or an exemption.
- Management Commentary: The filing states that director resignations were not related to any disagreements regarding operations, policies, or financial disclosures.
Investor Verification Checklist
- Verify the full text of the Certificate of Designation (Exhibit 3.1) for specific limitations and rights of the Series AA Preferred Stock.
- Confirm the impact of the 54% ownership concentration by Handok, Inc. and Genexine, Inc. on future corporate governance and strategic direction.
- Review the Schedule 14f-1 notice to understand the effective date of the new Board composition.
- Assess the potential for future dilution based on the weighted average anti-dilution formula and the $0.22 conversion price floor.
- Confirm the status of the amendment to the Certificate of Incorporation required to increase authorized Common Stock to 500,000,000 shares.